Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals. (2016)
Attributed to:
Rare disease use of clinical trial simulation for the chioce and optimization of study designs/Priomedchild Call/ER
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00280-016-3059-x
PubMed Identifier: 27220867
Publication URI: http://europepmc.org/abstract/MED/27220867
Type: Journal Article/Review
Volume: 78
Parent Publication: Cancer chemotherapy and pharmacology
Issue: 1
ISSN: 0344-5704